Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P42224: Variant p.Asp165Gly

Signal transducer and activator of transcription 1-alpha/beta
Gene: STAT1
Feedback?
Variant information Variant position: help 165 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Aspartate (D) to Glycine (G) at position 165 (D165G, p.Asp165Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In IMD31C; gain of function mutation associated with increased STAT1 phosphorylation due to impaired nuclear dephosphorylation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 165 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 750 The length of the canonical sequence.
Location on the sequence: help KVRNVKDKVMCIEHEIKSLE D LQDEYDFKCKTLQNREHETN The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         KVRNVKDKVMCIEHEIKSLEDLQDEYDFKCKTLQNREHETN

Mouse                         KVRNVKDQVMCIEQEIKTLEELQDEYDFKCKTSQNREGEAN

Pig                           KVRNVKDKVMCIEHEIKTLEDLQDEYDFKCKTLQNREHDTN

Caenorhabditis elegans        ------ENVFTVKQQMTELQK-------RAATL--------
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 750 Signal transducer and activator of transcription 1-alpha/beta
Coiled coil 136 – 317
Modified residue 175 – 175 N6-methyllysine
Mutagenesis 175 – 175 K -> A. No effect on IFN-alpha-induced STAT1 phosphorylation and nuclear translocation.
Helix 134 – 175



Literature citations
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.
Liu L.; Okada S.; Kong X.F.; Kreins A.Y.; Cypowyj S.; Abhyankar A.; Toubiana J.; Itan Y.; Audry M.; Nitschke P.; Masson C.; Toth B.; Flatot J.; Migaud M.; Chrabieh M.; Kochetkov T.; Bolze A.; Borghesi A.; Toulon A.; Hiller J.; Eyerich S.; Eyerich K.; Gulacsy V.; Chernyshova L.; Chernyshov V.; Bondarenko A.; Maria Cortes Grimaldo R.; Blancas-Galicia L.; Madrigal Beas I.M.; Roesler J.; Magdorf K.; Engelhard D.; Thumerelle C.; Burgel P.R.; Hoernes M.; Drexel B.; Seger R.; Kusuma T.; Jansson A.F.; Sawalle-Belohradsky J.; Belohradsky B.; Jouanguy E.; Bustamante J.; Bue M.; Karin N.; Wildbaum G.; Bodemer C.; Lortholary O.; Fischer A.; Blanche S.; Al-Muhsen S.; Reichenbach J.; Kobayashi M.; Rosales F.E.; Lozano C.T.; Kilic S.S.; Oleastro M.; Etzioni A.; Traidl-Hoffmann C.; Renner E.D.; Abel L.; Picard C.; Marodi L.; Boisson-Dupuis S.; Puel A.; Casanova J.L.;
J. Exp. Med. 208:1635-1648(2011)
Cited for: VARIANTS IMD31C GLY-165; HIS-165; ASN-170; ARG-174; ILE-202; VAL-202; VAL-267; PRO-271; GLN-274; TRP-274; ILE-286 AND ALA-288; CHARACTERIZATION OF VARIANTS IMD31C GLY-165 AND GLN-274; New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe.
Soltesz B.; Toth B.; Shabashova N.; Bondarenko A.; Okada S.; Cypowyj S.; Abhyankar A.; Csorba G.; Tasko S.; Sarkadi A.K.; Mehes L.; Rozsival P.; Neumann D.; Chernyshova L.; Tulassay Z.; Puel A.; Casanova J.L.; Sediva A.; Litzman J.; Marodi L.;
J. Med. Genet. 50:567-578(2013)
Cited for: VARIANTS IMD31C GLY-165; LYS-179; GLN-274; TRP-274; ARG-285 AND MET-385; CHARACTERIZATION OF VARIANTS IMD31C LYS-179; GLN-274; TRP-274; ARG-285 AND MET-385; CHARACTERIZATION OF VARIANT IMD31B CYS-701;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.